Ask AI
Back Back
ProCE Banner Activity

Practice-Changing Advances in CAR T-Cell Therapy Across Hematologic Malignancies

Clinical Thought

Read this expert-authored commentary to get up-to-date on the latest advances in CAR T-cell therapy for lymphomas and multiple myeloma. These include the removal of REMS for CAR T-cell therapy, the first FDA approval of CAR T for marginal zone lymphoma, and the multitude of new therapies in development.

Released: January 02, 2026

Begin Activity

Share

Faculty

Amrita Krishnan

Amrita Krishnan, MD, FACP

Director, Judy and Bernard Center for Myeloma, City of Hope
Nason Hollingsworth Family Chair Myeloma
Executive Director, Hematology, City of Hope Orange County
Professor Hematology/HCT
Irvine, California 
Krish Patel

Krish Patel, MD

Director, Lymphoma Research
Sarah Cannon Research Institute
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This educational activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with leukemia, lymphoma, or multiple myeloma eligible for CAR T-cell therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients and colleagues on the scientific rationales and clinical needs behind new approaches to CAR T-cell therapy in treatment of hematologic malignancies

  • Develop individualized treatment plans leveraging approved CAR T-cell therapies to optimize clinical outcomes in patients with hematologic malignancies based on the latest clinical evidence

  • Apply the most recent real-world and clinical trial data on CAR T-cell therapies to mitigate toxicity risk and support quality of life for patients with hematologic malignancies

  • Evaluate emerging data for novel CAR T-cell therapies and the potential implications for near-future clinical management of patients with hematologic malignancies

Disclosure

Primary Author

Amrita Krishnan, MD, FACP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche, Sanofi; individual publicly traded stock/stock options: Arcellx, Bristol Myers Squibb.

Krish Patel, MD: researcher (paid to institution): AbbVie, Adaptive, Adicet, Arvinas, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, Fate, Genenetech/Roche, Indapta, Janssen, Kite, Lilly, Loxo Oncology, MEI Pharma, Merck, Nuriz, Pfizer, Pharmacyclics, Sana, Xencor; consultant/advisor (paid to institution): AbbVie, AstraZeneca, Avencell, BeOne, Bristol Myers Squibb, Caribou Biosciences, Century Therapeutics, Genentech/Roche, Janssen, Lilly, Lyell Immunopharma, Merck, Sanofi; consultant/advisor: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Genentech/Roche, Kite, Lilly, Merck, Pfizer; speaker: Bristol Myers Squibb, Kite.